Sudo Biosciences is a biopharma company that designs and develops medicines that target the tyrosine kinase 2 (TYK2) pseudokinase domain.
Sudo Biosciences has raised $30.0M in total funding. The most recent round was Series B. The last funding was announced in February 2024.
Sudo Biosciences's investors include TPG, Dementia Discovery Fund, Frazier Life Sciences, Sanofi Ventures, Enavate Sciences.
Sudo Biosciences is headquartered in Carmel, United States.
Sudo Biosciences is a biopharma company that designs and develops medicines that target the tyrosine kinase 2 (TYK2) pseudokinase domain.
Sudo Biosciences is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Sudo Biosciences — Funding & Investors." VCBacked, February 13, 2024, https://www.vcbacked.co/company/sudo-biosciences. Accessed August 14, 2026.
VCBacked. (2024). Sudo Biosciences — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/sudo-biosciences
{{cite web |title=Sudo Biosciences — Funding & Investors |url=https://www.vcbacked.co/company/sudo-biosciences |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated